A conjugate of doxorubicin and an analog of Luteinizing Hormone-Releasing Hormone shows increased efficacy against oral and laryngeal cancers

Next »Oral Oncology
Volume 38, Issue 7 , Pages 657-663, October 2002

Linda J. Krebs
- Department of Physiology and Biophysics, and Department of Oral Biology, State University of New York at Buffalo, Buffalo, NY 14214, USA
- Institute for Lasers, Photonics and Biophotonics, Department of Chemistry, State University of New York at Buffalo, Buffalo, NY 14260, USA
- Corresponding author. Present address: University of Connecticut Health Center, Center for Molecular Medicine, 263 Farmington Avenue, MC 3101, Farmington, CT 06030, USA. Tel.: +1-860-679-2668; fax: +1-860-679-1920
Xiaopeng Wang
- Institute for Lasers, Photonics and Biophotonics, Department of Chemistry, State University of New York at Buffalo, Buffalo, NY 14260, USA
Atilla Nagy
- Veterans Affairs Medical Center and Tulane University School of Medicine, New Orleans, LA 70112, USA
Andrew V. Schally
- Veterans Affairs Medical Center and Tulane University School of Medicine, New Orleans, LA 70112, USA
Paras N. Prasad
- Institute for Lasers, Photonics and Biophotonics, Department of Chemistry, State University of New York at Buffalo, Buffalo, NY 14260, USA
Charles Liebow
- Department of Physiology and Biophysics, and Department of Oral Biology, State University of New York at Buffalo, Buffalo, NY 14214, USA
- Institute for Lasers, Photonics and Biophotonics, Department of Chemistry, State University of New York at Buffalo, Buffalo, NY 14260, USA